290 related articles for article (PubMed ID: 22139615)
1. Intravitreal bevacizumab for choroidal neovascularization secondary to Best vitelliform macular dystrophy in a 6-year-old child.
Chhablani J; Jalali S
Eur J Ophthalmol; 2012; 22(4):677-9. PubMed ID: 22139615
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
3. Functional and anatomic changes in bilateral choroidal neovascularization associated with vitelliform macular dystrophy after intravitreal bevacizumab.
Cennamo G; Cesarano I; Vecchio EC; Reibaldi M; de Crecchio G
J Ocul Pharmacol Ther; 2012 Dec; 28(6):643-6. PubMed ID: 22742532
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks: one year of follow-up.
El Matri L; Kort F; Bouraoui R; Karim B; Chebil A; Chaker N
Acta Ophthalmol; 2011 Nov; 89(7):641-6. PubMed ID: 21155980
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
[TBL] [Abstract][Full Text] [Related]
6. Treatment of choroidal neovascularization using intravitreal bevacizumab.
Pedersen R; Soliman W; Lund-Andersen H; Larsen M
Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
[TBL] [Abstract][Full Text] [Related]
8. Autosomal recessive best vitelliform macular dystrophy: report of a family and management of early-onset neovascular complications.
Iannaccone A; Kerr NC; Kinnick TR; Calzada JI; Stone EM
Arch Ophthalmol; 2011 Feb; 129(2):211-7. PubMed ID: 21320969
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results.
Mimoun G; Caillaux V; Querques G; Rothschild PR; Puche N; Souied EH
Retina; 2013 Mar; 33(3):513-21. PubMed ID: 23400081
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab for extrafoveal choroidal neovascularization after ocular trauma.
De Benedetto U; Battaglia Parodi M; Knutsson KA; Librando A; Bandello F; Lanzetta P; Iacono P
J Ocul Pharmacol Ther; 2012 Oct; 28(5):550-2. PubMed ID: 22554238
[TBL] [Abstract][Full Text] [Related]
12. [Intravitreal bevacizumab treatment for choroidal neovascularization in Best's disease].
Perol J; Wolff B; Sahel JA; Le Mer Y
J Fr Ophtalmol; 2011 May; 34(5):281-6. PubMed ID: 21507509
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
Zhang H; Liu ZL; Sun P; Gu F
Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
[TBL] [Abstract][Full Text] [Related]
14. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of intravitreal ranibizumab for choroidal neovascularization secondary to Best's disease: 3-year follow-up.
Ruiz-Moreno O; Calvo P; Ferrández B; Torrón C
Acta Ophthalmol; 2012 Nov; 90(7):e574-5. PubMed ID: 22339886
[No Abstract] [Full Text] [Related]
16. Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results.
Peiretti E; Vinci M; Fossarello M
Can J Ophthalmol; 2012 Feb; 47(1):28-33. PubMed ID: 22333848
[TBL] [Abstract][Full Text] [Related]
17. Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
Erol MK; Ozdemir O; Coban DT; Ceran BB; Bulut M
Semin Ophthalmol; 2014 Mar; 29(2):108-13. PubMed ID: 24409939
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Pro-re-Nata (PRN) and Treat and Extend Bevacizumab treatment protocols in Sorsby Fundus Dystrophy.
Tsokolas G; Almuhtaseb H; Lotery A
Eur J Ophthalmol; 2020 Jan; 30(1):26-33. PubMed ID: 30421618
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
